Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H19ClN2.C6H6O7.2Na |
Molecular Weight | 546.908 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].OC(=O)C(O)(CC([O-])=O)CC([O-])=O.ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=C(CC2)C=CC=N4
InChI
InChIKey=RDLARMRWOHXAFV-UHFFFAOYSA-L
InChI=1S/C19H19ClN2.C6H8O7.2Na/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13;7-3(8)1-6(13,5(11)12)2-4(9)10;;/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;/q;;2*+1/p-2
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C19H19ClN2 |
Molecular Weight | 310.821 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C6H6O7 |
Molecular Weight | 190.1076 |
Charge | -2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11243504Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11243504
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf
Desloratadine is an active, descarboethoxy metabolite of loratadine. It acts by selective inhibition of H1 histamine receptor and thus provides relief to patients with allergic rhinitis and chronic idiopathic urticaria. Desloratadine was approved by FDA and it is currently marketed under the name Clarinex (among the others).
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 |
0.87 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | CLARINEX Approved UseDesloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date1.00889277E12 |
|||
Palliative | CLARINEX Approved UseDesloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date1.00889277E12 |
|||
Palliative | CLARINEX Approved UseDesloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date1.00889277E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4 ng/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
56.9 ng × h/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27 h |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
84.5% |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: Page: p. 25 |
unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: Page: p. 25 |
Disc. AE: Somnolence, Abdominal pain... AEs leading to discontinuation/dose reduction: Somnolence (1 patient) Sources: Page: p. 25Abdominal pain (1 patient) |
45 mg 1 times / day multiple, oral Highest studied dose Dose: 45 mg, 1 times / day Route: oral Route: multiple Dose: 45 mg, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M+F Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 1 patient Disc. AE |
1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: Page: p. 25 |
unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: Page: p. 25 |
Somnolence | 1 patient Disc. AE |
1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: Page: p. 25 |
unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: Page: p. 25 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
likely | ||||
likely | no (pharmacogenomic study) Comment: pharmacogenotype 2C19 does not correlate with systemic exposure Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0 |
|||
likely | no (pharmacogenomic study) Comment: lack of correlation in between 2D6 genotype and 3-OH DCL formation Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0 |
|||
likely | weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. Page: 10.0 |
|||
Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 1.0 |
yes | |||
yes | weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Desloratadine: a new approach in the treatment of allergy as a systematic disease--pharmacology and clinical overview. Introduction. | 2001 |
|
Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. | 2001 Aug |
|
Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. | 2001 Aug |
|
Chronic idiopathic urticaria treatment. | 2001 Jul-Aug |
|
Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. | 2001 Mar |
|
Second-generation antihistamines in asthma therapy: is there a protective effect? | 2002 |
|
Impact and modulation of nasal obstruction. | 2002 |
|
Chronic urticaria: impact of allergic inflammation. | 2002 |
|
Therapeutic points of intervention and clinical implications: role of desloratadine. | 2002 |
|
Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. | 2002 |
|
Oral bioavailability of desloratadine is unaffected by food. | 2002 |
|
Comparative pharmacology of H1 antihistamines: clinical relevance. | 2002 Dec 16 |
|
Treatment of allergic rhinitis. | 2002 Dec 16 |
|
Severe hepatotoxicity after application of desloratadine and fluconazole. | 2003 |
|
Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. | 2003 Apr |
|
Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine. | 2003 Aug 13 |
|
Gateways to clinical trials. | 2003 Dec |
|
Interactions of olopatadine and selected antihistamines with model and natural membranes. | 2003 Dec |
|
Validation of a sensitive and automated 96-well solid-phase extraction liquid chromatography-tandem mass spectrometry method for the determination of desloratadine and 3-hydroxydesloratadine in human plasma. | 2003 Jul 25 |
|
The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis. | 2003 Jun |
|
Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. | 2003 Jun |
|
Double-stranded RNA viruses in a mycocinogenic strain of Cystofilobasidium infirmominiatum. | 2003 Mar |
|
Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. | 2003 Mar |
|
[Multicenter study of the effectiveness and tolerability of desloratadine in seasonal allergic rhinitis]. | 2003 May 25 |
|
A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. | 2003 Oct |
|
Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. | 2003 Oct |
|
Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma. | 2003 Oct 25 |
|
Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine. | 2004 Apr |
|
Anti-inflammatory activity of H1-receptor antagonists: review of recent experimental research. | 2004 Jan |
|
Gateways to clinical trials. | 2004 Jan-Feb |
|
High-performance liquid chromatographic method for the bioequivalence evaluation of desloratadine fumarate tablets in dogs. | 2004 Mar 10 |
Patents
Sample Use Guides
Adults and Adolescents 12 Years of Age and Over:
take 5 mg tablet once daily. Children 6 to Years of Age: take 2.5 mg tablet once daily. Children 12 Months to 5 Years of Age: take 1.25 mg tablet once daily. Children 6 to 11 Months of Age: 1 mg tablet once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7677235
Nasal epithelial cells (activated by 1 uM of histamine) were treated with 10 uM of desloratadine and the inhibitory activity of the drug on expression of ICAM-1 and HLA-DR was studied.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:17:15 UTC 2023
by
admin
on
Sat Dec 16 18:17:15 UTC 2023
|
Record UNII |
CZ422FA2AK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CZ422FA2AK
Created by
admin on Sat Dec 16 18:17:16 UTC 2023 , Edited by admin on Sat Dec 16 18:17:16 UTC 2023
|
PRIMARY | |||
|
1602766-05-1
Created by
admin on Sat Dec 16 18:17:16 UTC 2023 , Edited by admin on Sat Dec 16 18:17:16 UTC 2023
|
PRIMARY | |||
|
100000164231
Created by
admin on Sat Dec 16 18:17:16 UTC 2023 , Edited by admin on Sat Dec 16 18:17:16 UTC 2023
|
PRIMARY | |||
|
163203578
Created by
admin on Sat Dec 16 18:17:16 UTC 2023 , Edited by admin on Sat Dec 16 18:17:16 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|